There have been very few new therapies in the critical care arena over
the past half a century. Ikaria is committed to changing that.
We use our
scientific expertise to develop biotherapeutic solutions for the critical
care market. Our research and investigational work continues
to break new ground toward our goal of improving the clinical outcomes
for critically ill patients. INOMAX® (nitric
oxide) for inhalation is
our first commercialized product and demonstrates our ability to develop
therapies that meet the significant unmet needs of these patients.
But it’s only
just the start (see our
pipeline).
Read more about our scientific leaders and scientific endeavors.
GEOFFREY NICHOL, MB, ChB
Chief Medical Officer
Geoffrey Nichol, MB, ChB, has served as our Chief Medical Officer since May 2010. Prior to joining us, from September 2002 to January 2010, Dr. Nichol served as Senior Vice President of Product Development at Medarex, Inc., a specialty pharmaceutical company. From February 1996 to September 2002, Dr. Nichol served as Vice President at Novartis Pharmaceuticals, a global pharmaceutical company, where he also held the positions of Global Head of Respiratory, Bone and Hormone Replacement Therapy Clinical Research, Head of US Medical Affairs, and Global Head of Project Management. Dr. Nichol holds a BMedSc, MB, ChB, from Otago University Medical School (New Zealand), and an MBA from Warwick University (U.K.).
